Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (SARS)

A method for reducing the risk of severe acute respiratory syndrome (SARS) progression in a patient that has SARS, wherein the patient is infected with a SARS-coronavirus, wherein the method comprises determining a level of mid-regional pro-adrenomedullin (MR-proADM) in a sample from the patient, wherein said level indicates the severity of SARS progression, comprising prognosing a subsequent adverse event in the health of the patient, wherein the patient has been diagnosed with SARS, wherein the level of MR-proADM indicates the likelihood of a subsequent adverse event in the health of said patient and treating said patient to reduce the risk of SARS progression, wherein the treatment comprises one or more of a transfer to a clinical setting for intensified treatment, hospitalization, an escalation of therapeutic interventions, symptomatic treatment, treatment to reduce fever and/or pain, anti-inflammatory treatment, antiviral treatment, antibiotic treatment, oxygen support, invasive mechanical ventilation, non-invasive mechanical ventilation, renal replacement therapy, vasopressor use, fluid therapy, extracorporeal blood purification and/or organ protection.